Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 101 to 150 of 413

TitleTypeExpected publication date
Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessmentHealth technology evaluation
Digitally enabled therapy for chronic tic disorders and Tourette SyndromeMedical technologies guidance
Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implantsInterventional procedures guidance
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Technology appraisal guidanceTBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Technology appraisal guidanceTBC
Drug-eluting coronary stents for treating coronary artery disease: late-stage assessmentHealth technology evaluation
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]Technology appraisal guidanceTBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235Technology appraisal guidanceTBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]NICE guidelineTBC
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073Technology appraisal guidanceTBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]Technology appraisal guidanceTBC
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]Technology appraisal guidanceTBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]Technology appraisal guidanceTBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317Technology appraisal guidanceTBC
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]Technology appraisal guidance
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]Technology appraisal guidanceTBC
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)NICE guideline
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]Technology appraisal guidanceTBC
Efgartigimod for treating generalised myasthenia gravis [ID4003]Technology appraisal guidanceTBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Technology appraisal guidanceTBC
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]Technology appraisal guidanceTBC
Elafibranor for treating primary biliary cholangitis [ID6331]Technology appraisal guidanceTBC
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]Technology appraisal guidanceTBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]Technology appraisal guidanceTBC
Encorafenib with binimetinib for BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]Technology appraisal guidanceTBC
Endometriosis: diagnosis and management - diagnosing endometriosisNICE guidelineTBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaInterventional procedures guidanceTBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Technology appraisal guidance
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy [ID6396]Technology appraisal guidanceTBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]Technology appraisal guidanceTBC
Epilepsies in children, young people and adults (extraordinary review)NICE guidelineTBC
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]Technology appraisal guidance
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]Technology appraisal guidanceTBC
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]Technology appraisal guidanceTBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]Technology appraisal guidance
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]Technology appraisal guidance
Evobrutinib for treating relapsing multiple sclerosis [ID6313]Technology appraisal guidanceTBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Technology appraisal guidanceTBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Technology appraisal guidanceTBC
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]Technology appraisal guidanceTBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology testsDiagnostics guidanceTBC
Falls: assessment and prevention in older people and people 50 and over at higher risk (update)NICE guideline
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion [ID6197]Technology appraisal guidanceTBC
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]Technology appraisal guidance
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Technology appraisal guidanceTBC
Fertility problems: assessment and treatmentNICE guideline
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]Technology appraisal guidanceTBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Technology appraisal guidanceTBC
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]Technology appraisal guidanceTBC
Flow tDCSMedtech innovation briefingsTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All